Takinib Might Be Starting Point for Therapies Targeting Inflammatory Diseases, Study Finds

Takinib Might Be Starting Point for Therapies Targeting Inflammatory Diseases, Study Finds
Takinib, an inhibitor of the protein TAK1, was found to interrupt the inflammatory response central to a variety of autoimmune disorders, such as Crohn’s disease, research shows. The study, “Takinib, a Selective TAK1 Inhibitor, Broadens the Therapeutic Efficacy of TNF-α Inhibition for Cancer and Autoimmune Disease,” was published in the journal Cell Chemical Biology. Takinib is a

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *